FIBROBIOLOGICS INC (FBLG)
US31573L1052 - Common Stock
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
FibroBiologics Set to Join Russell 2000® Index
FibroBiologics Set to Join Russell 2000® Index
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
HOUSTON, June 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (
FibroBiologics Announces 2024 Annual Meeting of Stockholders
FibroBiologics Announces 2024 Annual Meeting of Stockholders
HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+...
FBLG Stock Earnings: FibroBiologics, Inc. – Common Stock Reported Results for Q1 2024
FibroBiologics, Inc. - Common Stock just reported results for the first quarter of 2024.
FibroBiologics Files 2024 First Quarter Report
FibroBiologics Files 2024 First Quarter Report
HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+...
FibroBiologics to Present at the BIO International Convention 2024
FibroBiologics to Present at the BIO International Convention 2024
HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+...
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
Next-generation cell therapies to target chronic diseases
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+...
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth checking out as we dive into all of the biggest movements worth reading about on Wednesday morning!
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment
/PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a...
FibroBiologics to Present at Advanced Wound Care Summit USA
/PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a...
FibroBiologics Appoints Ruben A. Garcia as General Counsel
/PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a...
FibroBiologics Files 2023 Form 10-K Annual Report
/PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics") a clinical-stage biotechnology company with 150+ patents issued and pending with a focus...
FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum
/PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on...
FibroLogics stock rallies 82% amid data presentation, SEC filing (NASDAQ:FBLG)
FibroBiologics (FBLG) stock rallied 82% on Tuesday after the company reported preclinical data and said it privately placed 65,447 shares at $15 per share. Read more here.
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
/PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and...
FibroBiologics Announces Three United States Patents for Fibroblast Technology
/PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and...
FibroBiologics Announces Three Japanese Patents on Fibroblast Technology
/PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and...